Committed to Improving Health Outcomes for Patients with Neurological Disorders

Mumbai, February 14, 2023:Global pharma major Lupin Limited (Lupin) today announced the launch of a world-class Neuro-rehabilitation center, Atharv Ability in Bandra Kurla Complex (BKC), Mumbai, India. The first-of-its-kind robotic and computer-assisted, multi-disciplinary neuro-rehabilitation center is one of the most advanced rehabilitation centers in the country.

Atharv Ability offers a range of rehabilitation programs for post-stroke patients, patients with traumatic brain injury, spinal cord injury, and pediatric neurological conditions as well as for other neurological conditions including Parkinsons, cerebral palsy and multiple sclerosis.

The neuro-rehabilitation center has a comprehensive suite of state-of-the-art equipment including an end-effector based robotic solution for gait and hand training, balance training and postural control, occupational therapy, speech therapy and swallowing therapy, cognitive behavioral therapy, aqua therapy, visual therapy, and virtual reality amongst others.

For the first time in India, Atharv Ability has introduced a dedicated home environment simulation space for “Activities of Daily Life” training that supports patient daily life and their interaction with the environment. The training improves their functionality and cognitive abilities and helps them integrate back into normal life.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “Neurological disorders and events lead to disability, creating an urgent need for multi-disciplinary centers with advanced therapeutic care delivered by neurological rehabilitation expertsunder one roof.This is why we have launched Atharv Ability, an innovative and futuristic neuro-rehabilitation center to improve health outcomes and quality of life of patients with neuro-disabilities through world-class patient-centric rehabilitation that is affordable and accessible for all.”

For more information on Atharv Ability, please visit https://atharvability.com

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com

for more information :
Follow us on Twitter: https://twitter.com/LupinGlobal/
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact:

Shweta Munjal
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com